AMGN
$186.97
Amgen
($1.37)
(.73%)
AMGN
Earnings Whisper ®
N/A
1st Quarter March 2019
Consensus:  $3.48
Revenue:  $5.58 Bil
Tuesday
Apr 30
4:00 PM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when AMGN reports earnings?
Beat
Meet
Miss

Where is AMGN's stock price going from here?
Up
Flat
Down
Stock chart of AMGN
Analysts
Summary of analysts' recommendations for AMGN
Score
Grade
Pivots
Resistance
$189.63
$189.05
$188.01

$187.43

Support
$186.39
$185.81
$184.77
Tweet
Growth
Description
Amgen Inc. discovers, develops and delivers innovative human therapeutics. A biotechnology pioneer, Amgen was one of the first companies to realize the new science's promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives.
Peers
BiogenBluebird BioGilead SciencesNeurocrine BiosciencesSeattle GeneticsNovavaxQiagen N.V.RepligenSangamo TherapeuticsBio-Techne